Laboratorio Italiano Biochimico Farmaceutico Lisapharma SpA
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Laboratorio Italiano Biochimico Farmaceutico Lisapharma SpA - overview
Established
1925
Location
Como, -, Italy
Primary Industry
Pharmaceuticals
About
Laboratorio Italiano Biochimico Farmaceutico Lisapharma SpA is an Italian pharmaceutical company specializing in the development and production of sterile injectable medicines and other pharmaceutical products for diverse therapeutic applications. Founded in 1925 in Como, Italy, Lisapharma produces sterile injectable medicines and operates under a trade sale structure. In July 2019, Shandong Sito Bio-technology Co. , Ltd.
acquired a majority stake in the company from Arcadia SGR and Azimut Libera Impresa for EUR 8. 8 million, representing a strategic pivot in ownership. Lisapharma specializes in the production of sterile injectable medicines, including sterile injectable drugs, non-sterile liquids, semi-solids, and medical devices. Their products are designed to ensure high-quality performance and efficacy, serving both Italian and multinational pharmaceutical companies.
Lisapharma operates in multiple international markets across Europe and Asia, leveraging extensive Marketing Authorizations to meet client needs. In the most recent financial year 2022, Lisapharma reported a revenue of EUR 12,512,459. 30, while the EBITDA for the same year was EUR -67,162. 80.
The company generates revenue primarily through contract manufacturing arrangements and partnerships with international pharmaceutical firms, utilizing a diversified approach to maintain a robust financial structure. Lisapharma aims to expand its footprint in international markets, particularly targeting regions in Asia and Europe for potential growth initiatives. The recent acquisition provides further capital to enhance product development and launch new products tailored to market demands. Following the trade sale in July 2019, the investment will support these expansion strategies and leverage the capabilities of Shandong Sito Bio-technology Co.
, Ltd. to foster growth.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.lisapharma.it
Verticals
Manufacturing
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Laboratorio Italiano Biochimico Farmaceutico Lisapharma SpA - timeline of key events
Laboratorio Italiano Biochimico Farmaceutico Lisapharma SpA - financials
| Fiscal Year Ended | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 13,276,095 | 17,483,884 | 22,225,773 | 27,271,763 | 27,963,933 | 27,264,214 | 19,676,949 | 16,245,468 | 17,170,770 | 13,533,608 | - | - | - |
| % Revenue Growth (YoY) | - | 31.7% | 27.1% | 22.7% | 2.5% | (2.5%) | (27.8%) | (17.4%) | 5.7% | (21.2%) | - | - | - |
| EBITDA (USD) | 667,025 | 1,269,746 | 2,022,978 | 1,636,733 | 2,506,633 | 2,243,291 | 742,996 | 620,985 | (723,143) | (4,704,037) | - | - | - |
| Operating Income (USD) | (90,933) | 450,594 | 1,201,893 | 823,257 | 1,528,493 | 1,085,200 | (492,894) | (753,417) | (2,057,015) | (5,895,388) | - | - | - |
| Operating Margin | (0.7%) | 2.6% | 5.4% | 3.0% | 5.5% | 4.0% | (2.5%) | (4.6%) | (12.0%) | (43.6%) | - | - | - |
| % EBITDA Margin | 5.0% | 7.3% | 9.1% | 6.0% | 9.0% | 8.2% | 3.8% | 3.8% | (4.2%) | (34.8%) | - | - | - |
| NET Income (USD) | (299,411) | 16,153 | 607,332 | 62,015 | 1,493,652 | 601,099 | (777,731) | (1,210,558) | (2,687,625) | (6,430,827) | - | - | - |
| % Net Margin | (2.3%) | 0.1% | 2.7% | 0.2% | 5.3% | 2.2% | (4.0%) | (7.5%) | (15.7%) | (47.5%) | - | - | - |
Laboratorio Italiano Biochimico Farmaceutico Lisapharma SpA - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | Laboratorio Italiano Biochimico Farmaceutico Lisapharma SpA | - | ||||||||
| Buyout | Completed | Laboratorio Italiano Biochimico Farmaceutico Lisapharma SpA | - |
Displaying 1 - 2 of 2
Laboratorio Italiano Biochimico Farmaceutico Lisapharma SpA - employee data
Laboratorio Italiano Biochimico Farmaceutico Lisapharma SpA - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Board Member | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.